Our results showed that treatment of patient-derived CRC-SCs with EM127 triggers the downregulation of c-MYC target genes, including CD44, SOX9, KLF4, NANOG, OCT4, SOX2, CCND1 (CSC markers) (Fig. 3c). The gene discussed is NANOG; the disease is colorectal carcinoma.